A population-based meta-analysis of circulating GFAP for cognition and dementia risk.
Autor: | Gonzales MM; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Wiedner C; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Wang CP; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; South Texas Veterans Health Care System, Geriatric Research, Education & Clinical Center, San Antonio, Texas, USA., Liu Q; Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Bis JC; Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA., Li Z; Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA., Himali JJ; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; The Framingham Heart Study, Framingham, Massachusetts, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.; Department of Biostatistics, Boston University School of Medicine, Boston, Massachusetts, USA., Ghosh S; The Framingham Heart Study, Framingham, Massachusetts, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Thomas EA; Brown Foundation of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA., Parent DM; Department of Pathology and Laboratory Medicine, and Biochemistry, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA., Kautz TF; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Pase MP; The Framingham Heart Study, Framingham, Massachusetts, USA.; School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria, Australia.; Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Aparicio HJ; The Framingham Heart Study, Framingham, Massachusetts, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Djoussé L; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Boston Veterans Affairs Healthcare System, Boston, Massachusetts, USA., Mukamal KJ; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Psaty BM; Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA.; Department of Epidemiology, University of Washington, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.; Department of Health Systems and Population Health, University of Washington, Seattle, Washington, USA., Longstreth WT Jr; Department of Epidemiology, University of Washington, Seattle, Washington, USA.; Department of Neurology, University of Washington, Seattle, Washington, USA., Mosley TH Jr; The MIND Center, University of Mississippi Medical Center, Jackson, Mississippi, USA., Gudnason V; Icelandic Heart Association Research Institute, Kópavogur, Iceland.; Department of Cardiology, University of Iceland, Reykjavik, Iceland., Mbangdadji D; Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA., Lopez OL; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Yaffe K; Department of Psychiatry, University of California, San Francisco, California, USA.; Department of Neurology, University of California, San Francisco, California, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.; San Francisco VA Medical Center, San Francisco, California, USA., Sidney S; Kaiser Permanente Medical Center Program, Oakland, California, USA., Bryan RN; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Nasrallah IM; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., DeCarli CS; Department of Neurology, University of California, Davis, California, USA., Beiser AS; The Framingham Heart Study, Framingham, Massachusetts, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.; Department of Biostatistics, Boston University School of Medicine, Boston, Massachusetts, USA., Launer LJ; Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA., Fornage M; Brown Foundation of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA., Tracy RP; Department of Pathology and Laboratory Medicine, and Biochemistry, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA., Seshadri S; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; The Framingham Heart Study, Framingham, Massachusetts, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Satizabal CL; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; The Framingham Heart Study, Framingham, Massachusetts, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2022 Oct; Vol. 9 (10), pp. 1574-1585. Date of Electronic Publication: 2022 Sep 03. |
DOI: | 10.1002/acn3.51652 |
Abstrakt: | Objective: Expression of glial fibrillary acidic protein (GFAP), a marker of reactive astrocytosis, colocalizes with neuropathology in the brain. Blood levels of GFAP have been associated with cognitive decline and dementia status. However, further examinations at a population-based level are necessary to broaden generalizability to community settings. Methods: Circulating GFAP levels were assayed using a Simoa HD-1 analyzer in 4338 adults without prevalent dementia from four longitudinal community-based cohort studies. The associations between GFAP levels with general cognition, total brain volume, and hippocampal volume were evaluated with separate linear regression models in each cohort with adjustment for age, sex, education, race, diabetes, systolic blood pressure, antihypertensive medication, body mass index, apolipoprotein E ε4 status, site, and time between GFAP blood draw and the outcome. Associations with incident all-cause and Alzheimer's disease dementia were evaluated with adjusted Cox proportional hazard models. Meta-analysis was performed on the estimates derived from each cohort using random-effects models. Results: Meta-analyses indicated that higher circulating GFAP associated with lower general cognition (ß = -0.09, [95% confidence interval [CI]: -0.15 to -0.03], p = 0.005), but not with total brain or hippocampal volume (p > 0.05). However, each standard deviation unit increase in log-transformed GFAP levels was significantly associated with a 2.5-fold higher risk of incident all-cause dementia (Hazard Ratio [HR]: 2.47 (95% CI: 1.52-4.01)) and Alzheimer's disease dementia (HR: 2.54 [95% CI: 1.42-4.53]) over up to 15-years of follow-up. Interpretation: Results support the potential role of circulating GFAP levels for aiding dementia risk prediction and improving clinical trial stratification in community settings. (© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |